Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01071018 | A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007) | PHASE1 | COMPLETED | 24 | — | — | Feb 1, 2010 | Sep 1, 2011 | Sep 7, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| QOD Schedule | EXPERIMENTAL | QOD Schedule, MK2206 every other day |
| QW Schedule | EXPERIMENTAL | QW Schedule, MK2206 once weekly |
| Name | Type | Description |
|---|---|---|
| MK2206 every other day | DRUG | Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles. |
| MK2206 once weekly | DRUG | Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles. |
Inclusion Criteria: * Patient must have confirmed locally advanced or metastatic solid tumors that have failed to respond to standard therapy, have gotten worse or have come back after existing therapy * Has adequate organ function * Is ECOG Performance Scale 0-1 * Has a negative urine pregnancy te...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |